SHLTN.SW SHL Telemedicine (SIX) +4.89% pre-market 09 Jan 2026: CHF1.18 insight
SHLTN.SW stock opened higher pre-market on 09 Jan 2026, trading at CHF 1.18 and showing a +4.89% move on volume 78,716. The jump puts SHL Telemedicine Ltd. (SIX) among early top gainers in Swiss trading. Investors are watching earnings cues, recent device partnerships, and short-term technical signals as drivers of today’s move.
Pre-market price action and intraday context
SHLTN.SW is trading at CHF 1.18 with a intraday high of CHF 1.20 and low of CHF 1.18. Volume is 78,716 versus an average volume of 20,872, signalling elevated interest. The 50-day average price is CHF 1.07 and the 200-day average is CHF 1.52, so current price sits below the long-term average.
Fundamentals and valuation snapshot for SHLTN.SW stock
SHL Telemedicine reports EPS of -0.76 and a trailing PE of -1.45, reflecting losses. Price-to-sales is 0.40 and price-to-book is 0.58, signalling low valuation relative to book value. Cash per share is CHF 0.81 and shareholders’ equity per share is CHF 2.36, while market cap is CHF 18,030,075, indicating a small-cap profile and higher idiosyncratic risk.
Technical snapshot and short-term indicators
Momentum is mixed: RSI is 49.50, stochastic %K 68.60. Bollinger upper band sits at CHF 1.23 and lower at CHF 0.95. The 50-day average is trending up at CHF 1.07, while the 200-day average at CHF 1.52 remains resistance. Recent price action shows short-term strength but no clear trend on ADX 8.57.
Meyka grade and model forecasts
Meyka AI rates SHLTN.SW with a score out of 100: Score 65.75 — Grade B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a monthly price of CHF 1.17, a quarterly price of CHF 1.34, and a yearly price of CHF 1.1095. Versus the current CHF 1.18, the quarterly forecast implies +13.56% upside and the yearly forecast implies -5.98% downside. Forecasts are model-based projections and not guarantees.
Catalysts, partnerships and sector context
SHL Telemedicine holds collaborations with Mayo Clinic and the Hebrew University for cardiac monitoring and AI tools, a key operational catalyst. The healthcare sector on SIX shows average PE 33.47 and recent YTD performance weak, making SHLTN.SW’s low valuation stand out. Upcoming earnings windows and FDA-related milestones remain primary catalysts.
Risks, liquidity and realistic price targets
Key risks include negative net margins (-50.05%), low current ratio 0.87, and thin market cap liquidity. For trading context, we set a conservative analyst range: base price target CHF 1.60 (+35.59%), bull CHF 2.20 (+86.44%), and downside support CHF 0.90 (-23.73%). These targets reflect recovery scenarios and continued operational pressure.
Final Thoughts
SHLTN.SW stock is a small-cap healthcare gainer in the pre-market session at CHF 1.18, driven by short-term buying and fundamental news flow. Valuation is low with price-to-sales 0.40 and price-to-book 0.58, but earnings remain negative and liquidity is limited. Meyka AI’s model shows mixed horizons: a quarterly target CHF 1.34 (implied +13.56%) and a yearly projection CHF 1.1095 (implied -5.98%). Our Meyka grade (B, HOLD) balances recovery potential from partnerships with ongoing margin and cashflow pressures. Traders should watch the next earnings windows and collaboration milestones. Forecasts are model-based projections and not guarantees. For deeper data, see the company site and our Meyka stock page for live updates and alerts.
FAQs
What drives the pre-market gain in SHLTN.SW stock?
Early buying appears linked to renewed interest in SHL’s partnerships and a technical bounce from the 50-day average. Low float and small market cap can magnify moves. Watch volume and news flow for confirmation.
What is Meyka AI’s grade for SHLTN.SW?
Meyka AI rates SHLTN.SW with a score out of 100: 65.75 — Grade B — Suggestion: HOLD. This factors sector comparison, growth, metrics, forecasts and consensus.
What price targets and forecasts exist for SHLTN.SW?
Meyka AI’s forecast model projects monthly CHF 1.17, quarterly CHF 1.34, and yearly CHF 1.1095. Suggested conservative target CHF 1.60, bull CHF 2.20, downside CHF 0.90.
Is SHLTN.SW stock suitable for long-term portfolios?
SHLTN.SW may suit risk-tolerant investors seeking healthcare exposure and small-cap upside. Ongoing losses, limited liquidity, and operational risk make it unsuitable for conservative, income-focused portfolios.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.